Research programme: autoimmune disorders therapeutics - DeliniaAlternative Names: DEL 106
Latest Information Update: 01 Feb 2017
At a glance
- Originator Delinia
- Class Proteins
- Mechanism of Action Interleukin-2 receptor agonists; Regulatory T-lymphocyte stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders